Management of patients with multidrug-resistant tuberculosis.

Lange, C; Aarnoutse, R E; Alffenaar, J W C; Bothamley, G; Brinkmann, F; Costa, J; Chesov, D; van Crevel, R; Dedicoat, M; Dominguez, J; Duarte, R; Grobbel, H P; Günther, Gunar; Guglielmetti, L; Heyckendorf, J; Kay, A W; Kirakosyan, O; Kirk, O; Koczulla, R A; Kudriashov, G G; ... (2019). Management of patients with multidrug-resistant tuberculosis. The international journal of tuberculosis and lung disease, 23(6), pp. 645-662. IUATLD 10.5588/ijtld.18.0622

[img] Text
document.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (194kB) | Request a copy

The emergence of multidrug-resistant tuberculosis (MDR-TB; defined as resistance to at least rifampicin and isoniazid) represents a growing threat to public health and economic growth. Never before in the history of mankind have more patients been affected by MDR-TB than is the case today. The World Health Organization reports that MDR-TB outcomes are poor despite staggeringly high management costs. Moreover, treatment is prolonged, adverse events are common, and the majority of affected patients do not receive adequate treatment. As MDR-TB strains are often resistant to one or more second-line anti-TB drugs, in-depth genotypic and phenotypic drug susceptibility testing is needed to construct personalised treatment regimens to improve treatment outcomes. For the first time in decades, the availability of novel drugs such as bedaquiline allow us to design potent and well-tolerated personalised MDR-TB treatment regimens based solely on oral drugs. In this article, we present management guidance to optimise the diagnosis, algorithm-based treatment, drug dosing and therapeutic drug monitoring, and the management of adverse events and comorbidities, associated with MDR-TB. We also discuss the role of surgery, physiotherapy, rehabilitation, palliative care and smoking cessation in patients with MDR-TB. We hope that incorporating these recommendations into patient care will be helpful in optimising treatment outcomes, and lead to more MDR-TB patients achieving a relapse-free cure.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Pneumology

UniBE Contributor:

Günther, Gunar

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1815-7920

Publisher:

IUATLD

Language:

English

Submitter:

Andrea Stettler

Date Deposited:

06 Jan 2020 11:20

Last Modified:

06 Jan 2020 11:28

Publisher DOI:

10.5588/ijtld.18.0622

PubMed ID:

31315696

BORIS DOI:

10.7892/boris.138000

URI:

https://boris.unibe.ch/id/eprint/138000

Actions (login required)

Edit item Edit item
Provide Feedback